Common adverse effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort, particularly during the initial weeks of treatment
Semaglutide has been shown to help lower systolic blood pressure, which in turn reduces the workload on kidneys and supports overall renal health
Your improved metabolic markers would not trigger any flags
Research is needed to help illustrate the size and nature of access gaps so that we can design better coverage policies. Ultimately, there is a need for policymakers to recognize that factors unrelated to whether an individual has a medical necessity for treatment can affect whether or not a person is likely to receive these medications, says study lead author Meghan Podolsky (SPH24), research fellow in the Department of Global Health and an SPH alum who completed the MS program in epidemiology last year
You might not have the energy for a 15-mile hike the day after your injection
Either is defensible, but semaglutide carries the cardiovascular outcomes label, so it earns the first slot